Press Releases – CellCentric

Press and media

Press releases

More regular updates and key information, updates and news can be found on the CellCentric LinkedIn page.

CellCentric strengthens Board and executive leadership with appointments of Paolo Pucci and Jason Cavalier

8 September 2026 Press Release

CellCentric Announces Oversubscribed $220 Million Series D Financing to Advance Pivotal Trials of Inobrodib in Multiple Myeloma

6 May 2026 Press Release

CellCentric Initiates DOMMINO-1, a Pivotal Phase 2 Clinical Trial of Inobrodib in Combination with Pomalidomide and Dexamethasone (InoPd) in Relapsed or Refractory Multiple Myeloma

31 March 2026 Press Release

CellCentric Presents Positive Phase 2 Dose Optimization Data for Inobrodib in Multiple Myeloma at ASH Annual Meeting

7 December 2025 Press Release

CellCentric to Host Investor Event and Present Dose Optimization Data from Phase 2 Study of Inobrodib for Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting

3 November 2025 Press Release

CellCentric Announces Completion of Enrollment for Dose Optimization Cohorts in Phase 2 Study for Multiple Myeloma

9 September 2025 Press Release

CellCentric Announces First Patients Dosed with Inobrodib in Combination with Bispecific Antibodies in Multiple Myeloma

3 September 2025 Press Release

CellCentric to Participate in Upcoming Investor Conferences

5 August 2025 Press Release

CellCentric secures $120 million investment to advance inobrodib for treating multiple myeloma

19 May 2025 Press Release

cell-centric-expands-to-US-office-Boston

CellCentric Expands US Presence with New Office in Boston

2 April 2025 Press Release

CellCentric expands executive team with new Chief Strategy Officer

13 January 2025 Press Release

CellCentic Presents Latest Clinical Data at ASH: Promising Efficacy and Safety in Multiple Myeloma

10 December 2024 Press Release

Inobrodib

A first-in-class oral
anti-cancer drug